Gemtuzumab Ozogamicin (CD33) 抗
体, 单克隆-Gemtuzumab Ozogamicin (CD33) Antibody, Monoclonal- ￥22
- ProSci
- 美国
- PSI-10-788-0.1mg
- 2025年07月09日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Store at -80℃
- 保质期：
1年
- 级别：
科研级别
- 库存：
100
- 供应商：
艾美捷科技
- 抗体英文名：
Gemtuzumab Ozogamicin (CD33) Antibody, Monoclonal
- 抗体名：
Gemtuzumab Ozogamicin (CD33) Antibody, Monoclonal
- 规格：
0.1mg
Gemtuzumab Ozogamicin (CD33) 抗体, 单克隆，Gemtuzumab Ozogamicin (CD33) Antibody, Monoclonal，Gemtuzumab Ozogamicin (CD33) 抗体, 单克隆,Gemtuzumab Ozogamicin (CD33) Antibody, Monoclonal
产品名称：Gemtuzumab Ozogamicin (CD33) 抗体, 单克隆-Gemtuzumab Ozogamicin (CD33) Antibody, Monoclonal
产品货号：PSI-10-788-0.1mg
产品规格：0.1mg
背景资料：Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.
保存建议：Gemtuzumab Ozogamicin (CD33) 抗体, 单克隆-Gemtuzumab Ozogamicin (CD33) Antibody, MonoclonalStore at -80℃
应用类型：
点击：Gemtuzumab Ozogamicin (CD33) 抗体, 单克隆-Gemtuzumab Ozogamicin (CD33) Antibody, Monoclonal查看更详细产品说明，更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论，请点击查看艾美捷特色产品中心。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验瘤和白血病等。Mylotarg是由抗CD33分子的单抗和抗肿瘤抗生素calicheamicin连接的偶联物，在抗肿瘤单抗药物中，是第1个于2000年获批准上市的药物与单抗偶联物de Vetten[12]等用抗CD33-Calicheamicin偶合剂（gemtuzumab ozogamicin， CMA-676）治疗1例Ph’染色体阳性AML，用CMA-676单独用药2次，即获细胞形态学和细胞遗传学水平的CR，用实时PCR的方法检查，发现该制剂可杀灭骨髓内3个log的肿瘤细胞。。2、放射免疫偶联物将放射性核素连接在单抗
AntibodyCytotoxic Agent Conjugates: Preparation and Characterization
cytotoxic agents that inhibit essential cellular targets such as microtubules or DNA. Antibody–cytotoxic agent conjugates (ACCs) against several types of cancer are currently in advanced stages of clinical trials and one, gemtuzumab ozogamicin (Mylotarg�
【翻译】Development trends for monoclonal antibody cancer therapeutics
%) were drug–mAb conjugates, although an equal number of drug and protein immunoconjugates (6 candidates each) are now in the clinic. Only one immunotoxin, gemtuzumab ozogamicin (Mylotarg; UCB/Wyeth), a humanized mAb conjugated to calicheamicin
技术资料暂无技术资料 索取技术资料
